Xi Z X, Stein E A
Department of Cellular Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee 53226, USA.
J Pharmacol Exp Ther. 2000 Aug;294(2):613-9.
Opiate reinforcement has been hypothesized to be mediated by an inhibition of mesolimbic gamma-aminobutyric acid (GABA) release that subsequently disinhibits ventral tegmental area (VTA) dopamine neurons. In support of this hypothesis, this study demonstrates that when administered directly into the lateral ventricle, the VTA, or the ventral pallidum, but not the nucleus accumbens, gamma-vinyl-GABA (GVG, an irreversible GABA-transaminase inhibitor, 20-50 microg) dose dependently blocked heroin (0.06 mg/kg) self-administration (SA), as assessed by an increase in heroin SA at low doses of GVG and an initial increase followed 1 to 2 h later by a blockade of heroin SA at higher GVG doses. This effect lasted 3 to 5 days. In drug-naïve rats, intra-VTA GVG pretreatment also prevented or delayed acquisition of heroin SA for 2 days. This GVG effect was prevented or reversed by systemic or intra-VTA pretreatment with the GABA(B) antagonist 2-hydroxysaclofen, but not the GABA(A) antagonist bicuculline. Similarly, coadministration of heroin with aminooxy-acetic acid (1-4 mg/kg) or ethanolamine-O-sulfate (50-100 mg/kg), two reversible GABA transaminase inhibitors, dose dependently reduced heroin reinforcement. Coadministration of (+/-)-nipecotic acid (0.1-5 mg/kg) with heroin, or intra-VTA or -ventral pallidum pretreatment with (+/-)-nipecotic acid (10 microg) or NO-711 (2 microg), two GABA uptake inhibitors, significantly increased heroin SA behavior, an effect also blocked by systemic 2-hydroxysaclofen, but not bicuculline. Taken together, these experiments, for the first time, demonstrate that pharmacological elevation of mesolimbic GABA concentration blocks heroin reinforcement by activating GABA(B) receptors, supporting the GABAergic hypothesis of opiate reinforcement and the incorporation of GABA agents in opiate abuse treatment.
阿片类药物强化作用被假定为由中脑边缘γ-氨基丁酸(GABA)释放的抑制所介导,这种抑制随后解除对腹侧被盖区(VTA)多巴胺能神经元的抑制。为支持这一假说,本研究表明,当直接注入侧脑室、VTA或腹侧苍白球,但不注入伏隔核时,γ-乙烯基-GABA(GVG,一种不可逆的GABA转氨酶抑制剂,20 - 50微克)剂量依赖性地阻断海洛因(0.06毫克/千克)的自我给药(SA),低剂量GVG时海洛因SA增加,高剂量GVG时最初增加随后1至2小时后海洛因SA被阻断,以此来评估。这种作用持续3至5天。在未接触过药物的大鼠中,VTA内GVG预处理也可预防或延迟海洛因SA的习得2天。这种GVG作用可被GABA(B)拮抗剂2-羟基氯芬全身或VTA内预处理预防或逆转,但不能被GABA(A)拮抗剂荷包牡丹碱逆转。同样,海洛因与两种可逆的GABA转氨酶抑制剂氨氧基乙酸(1 - 4毫克/千克)或乙醇胺-O-硫酸盐(50 - 100毫克/千克)共同给药,剂量依赖性地降低海洛因强化作用。(±)-尼克酸(0.1 - 5毫克/千克)与海洛因共同给药,或(±)-尼克酸(10微克)或NO - 711(2微克)这两种GABA摄取抑制剂在VTA或腹侧苍白球内预处理,显著增加海洛因SA行为,这种作用也被全身2-羟基氯芬阻断,但不被荷包牡丹碱阻断。综上所述,这些实验首次证明,中脑边缘GABA浓度的药理学升高通过激活GABA(B)受体阻断海洛因强化作用,支持阿片类药物强化作用的GABA能假说以及GABA药物在阿片类药物滥用治疗中的应用。